Related Experiment Video
Updated: Oct 1, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target
Yuka Tanaka1, Maho Murata1, Keiko Tanegashima1
1Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka, 812-8582, Japan.
Abstract:
Angiosarcoma is a rare, life-threatening soft tissue sarcoma with malignant endothelial cells that is mainly found in the skin. Multidisciplinary approaches are used to treat patients with unresectable metastasized lesions; considering the cellular origin of angiosarcoma, anti-angiogenic therapy has also been used recently. However, these treatments have limited efficacy, and the survival rate remains low. Thus, more effective treatments need to be developed. Nectin cell adhesion molecule 4 (NECTIN4) is highly expressed in malignant tumors and promotes tumor progression. Thus, NECTIN4 is expected to be a novel therapeutic target for cancer. However, the significance of NECTIN4 in angiosarcoma remains unknown. Using immunohistochemistry, we investigated NECTIN4 expression in 74 tissue samples from angiosarcoma patients, finding variable NECTIN4 expression. In addition, we investigated NECTIN4 expression and function in human angiosarcoma cell lines. NECTIN4 expression was higher in angiosarcoma cells than normal endothelial cells, and angiosarcoma cells were sensitive to monomethyl auristatin E, the cytotoxic part of a NECTIN4-targetting antibody-drug conjugate. NECTIN4 knockdown inhibited the proliferation and angiogenesis of angiosarcoma cells, and Src kinase signaling was shown to be involved in NECTIN4 function, at least in part. NECTIN4-targeted therapy has the potential to be a novel treatment strategy for angiosarcoma.
Insights
Nectin cell adhesion molecule 4 (NECTIN4) is highly expressed in angiosarcoma, a rare cancer. Targeting NECTIN4 shows potential for new angiosarcoma treatments, inhibiting cancer cell growth and blood vessel formation.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Angiosarcoma is a rare, aggressive soft tissue sarcoma with poor prognosis.
- Current treatments for unresectable or metastatic angiosarcoma have limited efficacy.
- Nectin cell adhesion molecule 4 (NECTIN4) is implicated in various cancers, but its role in angiosarcoma is unclear.
Purpose of the Study:
- To investigate the expression and function of NECTIN4 in angiosarcoma.
- To evaluate NECTIN4 as a potential therapeutic target for angiosarcoma.
Main Methods:
- Immunohistochemistry was used to analyze NECTIN4 expression in 74 angiosarcoma tissue samples.
- NECTIN4 expression and function were studied in human angiosarcoma cell lines.
- Nectin cell adhesion molecule 4 (NECTIN4) knockdown and sensitivity to antibody-drug conjugates were assessed.
Main Results:
- NECTIN4 was found to be highly expressed in angiosarcoma cells compared to normal endothelial cells.
- Angiosarcoma cells showed sensitivity to NECTIN4-targeted antibody-drug conjugates.
- NECTIN4 knockdown suppressed angiosarcoma cell proliferation and angiogenesis, involving Src kinase signaling.
Conclusions:
- Nectin cell adhesion molecule 4 (NECTIN4) is a promising therapeutic target for angiosarcoma.
- Targeted therapies against NECTIN4 may offer a novel treatment strategy for this rare cancer.
- Further research into NECTIN4-targeted therapies is warranted for angiosarcoma treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Non-Canonical Wnt Signaling Pathways
Intracellular Signaling Affects Focal Adhesions
Some...
Canonical Wnt Signaling Pathway

